U.S. markets closed
  • S&P Futures

    4,393.25
    -1.25 (-0.03%)
     
  • Dow Futures

    34,931.00
    -22.00 (-0.06%)
     
  • Nasdaq Futures

    14,933.75
    -14.00 (-0.09%)
     
  • Russell 2000 Futures

    2,192.50
    +5.80 (+0.27%)
     
  • Crude Oil

    72.10
    +0.45 (+0.63%)
     
  • Gold

    1,802.00
    +2.20 (+0.12%)
     
  • Silver

    24.77
    +0.13 (+0.51%)
     
  • EUR/USD

    1.1826
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    1.2340
    -0.0420 (-3.29%)
     
  • Vix

    19.36
    +1.78 (+10.13%)
     
  • GBP/USD

    1.3885
    +0.0007 (+0.05%)
     
  • USD/JPY

    109.8430
    +0.0760 (+0.07%)
     
  • BTC-USD

    39,764.72
    +2,828.21 (+7.66%)
     
  • CMC Crypto 200

    933.09
    +56.86 (+6.49%)
     
  • FTSE 100

    6,996.08
    -29.35 (-0.42%)
     
  • Nikkei 225

    27,767.81
    -202.41 (-0.72%)
     

How Much Did ADMA Biologics'(NASDAQ:ADMA) Shareholders Earn From Share Price Movements Over The Last Five Years?

·2 min read

Some stocks are best avoided. We really hate to see fellow investors lose their hard-earned money. For example, we sympathize with anyone who was caught holding ADMA Biologics, Inc. (NASDAQ:ADMA) during the five years that saw its share price drop a whopping 77%. And it's not just long term holders hurting, because the stock is down 50% in the last year. But it's up 9.0% in the last week.

Check out our latest analysis for ADMA Biologics

Because ADMA Biologics made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

In the last half decade, ADMA Biologics saw its revenue increase by 34% per year. That's better than most loss-making companies. So on the face of it we're really surprised to see the share price has averaged a fall of 12% each year, in the same time period. It could be that the stock was over-hyped before. While there might be an opportunity here, you'd want to take a close look at the balance sheet strength.

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

earnings-and-revenue-growth
earnings-and-revenue-growth

We like that insiders have been buying shares in the last twelve months. Even so, future earnings will be far more important to whether current shareholders make money. This free report showing analyst forecasts should help you form a view on ADMA Biologics

A Different Perspective

Investors in ADMA Biologics had a tough year, with a total loss of 50%, against a market gain of about 36%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 12% over the last half decade. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Consider risks, for instance. Every company has them, and we've spotted 3 warning signs for ADMA Biologics you should know about.

ADMA Biologics is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.